Cargando…
Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573311/ https://www.ncbi.nlm.nih.gov/pubmed/34750508 http://dx.doi.org/10.1038/s41375-021-01466-0 |
| _version_ | 1784595396617568256 |
|---|---|
| author | Spanjaart, Anne Mea Ljungman, Per de La Camara, Rafael Tridello, Gloria Ortiz-Maldonado, Valentín Urbano-Ispizua, Alvaro Barba, Pere Kwon, Mi Caballero, Dolores Sesques, Pierre Bachy, Emmanuel Di Blasi, Roberta Thieblemont, Catherine Calkoen, Friso Mutsaers, Pim Maertens, Johan Giannoni, Livia Nicholson, Emma Collin, Matthew Vaz, Carlos Pinho Metafuni, Elisabetta Martinez-Lopez, Joaquin Dignan, Fiona L. Ribera, Josep-Maria Nagler, Arnon Folber, Frantisek Sanderson, Robin Bloor, Adrian Ciceri, Fabio Knelange, Nina Ayuk, Francis Kroger, Nicolaus Kersten, Marie José Mielke, Stephan |
| author_facet | Spanjaart, Anne Mea Ljungman, Per de La Camara, Rafael Tridello, Gloria Ortiz-Maldonado, Valentín Urbano-Ispizua, Alvaro Barba, Pere Kwon, Mi Caballero, Dolores Sesques, Pierre Bachy, Emmanuel Di Blasi, Roberta Thieblemont, Catherine Calkoen, Friso Mutsaers, Pim Maertens, Johan Giannoni, Livia Nicholson, Emma Collin, Matthew Vaz, Carlos Pinho Metafuni, Elisabetta Martinez-Lopez, Joaquin Dignan, Fiona L. Ribera, Josep-Maria Nagler, Arnon Folber, Frantisek Sanderson, Robin Bloor, Adrian Ciceri, Fabio Knelange, Nina Ayuk, Francis Kroger, Nicolaus Kersten, Marie José Mielke, Stephan |
| author_sort | Spanjaart, Anne Mea |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8573311 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85733112021-11-08 Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group Spanjaart, Anne Mea Ljungman, Per de La Camara, Rafael Tridello, Gloria Ortiz-Maldonado, Valentín Urbano-Ispizua, Alvaro Barba, Pere Kwon, Mi Caballero, Dolores Sesques, Pierre Bachy, Emmanuel Di Blasi, Roberta Thieblemont, Catherine Calkoen, Friso Mutsaers, Pim Maertens, Johan Giannoni, Livia Nicholson, Emma Collin, Matthew Vaz, Carlos Pinho Metafuni, Elisabetta Martinez-Lopez, Joaquin Dignan, Fiona L. Ribera, Josep-Maria Nagler, Arnon Folber, Frantisek Sanderson, Robin Bloor, Adrian Ciceri, Fabio Knelange, Nina Ayuk, Francis Kroger, Nicolaus Kersten, Marie José Mielke, Stephan Leukemia Letter Nature Publishing Group UK 2021-11-08 2021 /pmc/articles/PMC8573311/ /pubmed/34750508 http://dx.doi.org/10.1038/s41375-021-01466-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Letter Spanjaart, Anne Mea Ljungman, Per de La Camara, Rafael Tridello, Gloria Ortiz-Maldonado, Valentín Urbano-Ispizua, Alvaro Barba, Pere Kwon, Mi Caballero, Dolores Sesques, Pierre Bachy, Emmanuel Di Blasi, Roberta Thieblemont, Catherine Calkoen, Friso Mutsaers, Pim Maertens, Johan Giannoni, Livia Nicholson, Emma Collin, Matthew Vaz, Carlos Pinho Metafuni, Elisabetta Martinez-Lopez, Joaquin Dignan, Fiona L. Ribera, Josep-Maria Nagler, Arnon Folber, Frantisek Sanderson, Robin Bloor, Adrian Ciceri, Fabio Knelange, Nina Ayuk, Francis Kroger, Nicolaus Kersten, Marie José Mielke, Stephan Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group |
| title | Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group |
| title_full | Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group |
| title_fullStr | Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group |
| title_full_unstemmed | Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group |
| title_short | Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group |
| title_sort | poor outcome of patients with covid-19 after car t-cell therapy for b-cell malignancies: results of a multicenter study on behalf of the european society for blood and marrow transplantation (ebmt) infectious diseases working party and the european hematology association (eha) lymphoma group |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573311/ https://www.ncbi.nlm.nih.gov/pubmed/34750508 http://dx.doi.org/10.1038/s41375-021-01466-0 |
| work_keys_str_mv | AT spanjaartannemea pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT ljungmanper pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT delacamararafael pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT tridellogloria pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT ortizmaldonadovalentin pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT urbanoispizuaalvaro pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT barbapere pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT kwonmi pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT caballerodolores pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT sesquespierre pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT bachyemmanuel pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT diblasiroberta pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT thieblemontcatherine pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT calkoenfriso pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT mutsaerspim pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT maertensjohan pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT giannonilivia pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT nicholsonemma pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT collinmatthew pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT vazcarlospinho pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT metafunielisabetta pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT martinezlopezjoaquin pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT dignanfional pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT riberajosepmaria pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT naglerarnon pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT folberfrantisek pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT sandersonrobin pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT blooradrian pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT cicerifabio pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT knelangenina pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT ayukfrancis pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT krogernicolaus pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT kerstenmariejose pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup AT mielkestephan pooroutcomeofpatientswithcovid19aftercartcelltherapyforbcellmalignanciesresultsofamulticenterstudyonbehalfoftheeuropeansocietyforbloodandmarrowtransplantationebmtinfectiousdiseasesworkingpartyandtheeuropeanhematologyassociationehalymphomagroup |